SCHEMBL15340822

SCHEMBL15340822

CN1CCN(CCCN(C)N(C)C)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.41
SIGMAR1 Q99720 2/20 0.39
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CSNK2A3 Q8NEV1 1/20 0.37
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
MAPT P10636 1/20 0.34
KDM1A O60341 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
PIM1 P11309 1/20 0.34
DRD3 P35462 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20332905 0.84 PAOX (0.45) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL7029723 0.82 ALOX15 (0.46) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL21634183 0.79 SIGMAR1 (0.45) PAOXSIGMAR1
SCHEMBL20332960 0.78 PAOX (0.41) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL16720920 0.77 SIGMAR1 (0.44) SIGMAR1CHRM2
SCHEMBL1782004 0.76 PAOX (0.47) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL25784727 0.76 PAOX (0.42) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL6663287 0.75 PAOX (0.60) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL6657767 0.75 PAOX (0.54) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1
SCHEMBL20234244 0.75 PAOX (0.60) PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281389-A1 NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2013-10-24 US disclosed
US-20130281389-A1 NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281389-A1 NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA XPO1, XPOT, DDB1 PAOX 3998/4885SIGMAR1 1879/4885CSNK2A2 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.